Namibia Health News API

{
    "totalArticles": 1739,
    "articles": [
        {
            "id": "6fa579339b15c25736f22aadc8125c02",
            "title": "Ivermectin was touted as a cure for COVID, now it’s being tested for cancer. But what can it actually treat?",
            "description": "Ivermectin has been proposed as a treatment for a number of diseases. Here’s what the science actually says.",
            "content": "Ivermectin was originally celebrated as a revolutionary treatment for parasitic disease in humans and animals. It has since evolved into a focal point of misinformation and heated debate.\nDuring the early part of the COVID pandemic, it was touted on ... [5365 chars]",
            "url": "https://theconversation.com/ivermectin-was-touted-as-a-cure-for-covid-now-its-being-tested-for-cancer-but-what-can-it-actually-treat-276180",
            "image": "https://images.theconversation.com/files/720067/original/file-20260224-57-oemnfs.jpg?ixlib=rb-4.1.0&rect=0%2C628%2C6000%2C3000&q=45&auto=format&w=1356&h=668&fit=crop",
            "publishedAt": "2026-02-24T19:10:48Z",
            "lang": "en",
            "source": {
                "id": "344b3e5c4a3152c0cbebe5418ae064b7",
                "name": "The Conversation",
                "url": "https://theconversation.com"
            }
        },
        {
            "id": "49319f6caf090822d98cf88cb7aca222",
            "title": "French study confirms efficacy of on-demand PrEP",
            "description": "Eight years after it started, the final results of a large French study that offered a choice of daily or event-driven oral PrEP (using tenofovir disoproxil/emtricitabine) were presented at the Conference on Retroviruses and Opportunistic Infections (CROI 2026) in Denver, US yesterday.",
            "content": "Eight years after it started, the final results of a large French study that offered a choice of daily or event-driven oral PrEP (using tenofovir disoproxil/emtricitabine) were presented at the Conference on Retroviruses and Opportunistic Infections ... [5006 chars]",
            "url": "https://www.aidsmap.com/news/feb-2026/french-study-confirms-efficacy-demand-prep",
            "image": "https://www.aidsmap.com/sites/default/files/styles/aidsmap_social_default/public/2026-02/aidsmap%202000x1300-jean-michel-molina.png?itok=m8B2lp6t",
            "publishedAt": "2026-02-24T16:10:00Z",
            "lang": "en",
            "source": {
                "id": "675d07a0f827bffe57bc261462fba8c6",
                "name": "Aidsmap",
                "url": "https://www.aidsmap.com"
            }
        },
        {
            "id": "b9ed0b95e7d9b993e863945361b66fb2",
            "title": "HIV patients show lower steatotic liver disease with ViiV’s Dovato vs Biktarvy",
            "description": "Patients with HIV showed lower cases of steatotic liver disease when switched to ViiV Healthcare’s Dovato compared to Biktarvy.",
            "content": "Patients with HIV showed lower cases of steatotic liver disease when switched to ViiV Healthcare’s Dovato compared to Biktarvy.\nIn the Phase IV PASO DOBLE study (NCT04884139), 29% of patients who started Dovato (dolutegravir/lamivudine (DTG/3TC)) exp... [2135 chars]",
            "url": "https://www.clinicaltrialsarena.com/news/hiv-patients-show-lower-steatotic-liver-disease-with-viivs-dovato-vs-biktarvy/",
            "image": "https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2026/02/shutterstock_2486304439.jpg",
            "publishedAt": "2026-02-24T11:22:08Z",
            "lang": "en",
            "source": {
                "id": "5fc6401b64c5c4ee117332a7a598b722",
                "name": "Clinical Trials Arena",
                "url": "https://www.clinicaltrialsarena.com"
            }
        }
    ]
}